Research programme: neuronal nitric oxide synthase inhibitors - Pfizer
Alternative Names: CP 536404; CP 601073; CP 695516Latest Information Update: 13 Aug 2009
Price :
$50 *
At a glance
- Originator Pfizer
- Class
- Mechanism of Action Nitric oxide synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Craniocerebral trauma; Neurological disorders; Neuropathic pain; Parkinson's disease; Stroke
Most Recent Events
- 13 Aug 2009 No development reported - Preclinical for Alzheimer's disease in USA (IV)
- 13 Aug 2009 No development reported - Preclinical for Head injuries in USA (IV)
- 13 Aug 2009 No development reported - Preclinical for Neurological disorders in USA (IV)